CB 618

Drug Profile

CB 618

Alternative Names: CB-238,618; CB-618

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cubist Pharmaceuticals
  • Developer Merck & Co
  • Class Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 01 Apr 2015 Cubist Pharmaceuticals completes a phase-I clinical trial in Gram-negative infections in USA (IV) (NCT02341599)
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 14 Jan 2015 Phase-I clinical trials in Gram-negative infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top